Graphite Bio
Graphite Bio raises $238M Series B at $1B valuation
Quick Facts
Graphite Bio: Series B Funding Round
Graphite Bio has successfully raised $238M in Series B funding, reaching a valuation of $1B.
Company Overview
Precision genetic medicines
Funding Details
The Series B round was led by ARCH Venture Partners, with participation from Vida Ventures, Norwest Venture Partners, Samsara BioCapital.
Company Information
- Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2019
- Employees: 150+
- Category: Biotech
Investment
Graphite Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series B
- Vida Ventures: Verified investor in Series B
- Norwest Venture Partners: Verified investor in Series B
- Samsara BioCapital: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...